 | Up a level |
2022
Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140. S. 19 - 24. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2020
Hillmen, Peter, Brown, Jennifer R., Eichhorst, Barbara F., Lamanna, Nicole 
ORCID: 0000-0003-3331-9491, O'Brien, Susan M., Qiu, Lugui, Salmi, Tommi, Hilger, James, Wu, Kenneth, Cohen, Aileen, Huang, Jane and Tam, Constantine S.
(2020).
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol., 16 (10).
S. 517 - 524.
LONDON:
FUTURE MEDICINE LTD.
ISSN 1744-8301